Pharmicell Co Ltd

Pharmicell maintains a strong liquidity position with a current ratio of 9.82, indicating a significant buffer of current assets over current liabilities. The company holds KRW 5,025,559,800 in cash and equivalents, which is a substantial portion of its total assets of KRW 90,308,735,580. The debt-to-equity ratio is 0.01, reflecting a conservative capital structure with minimal long-term debt obligations of KRW 646,320,930.

In terms of profitability, Pharmicell reported a net income of KRW 2,827,787,480 and an operating income of KRW 2,234,314,540 in the latest period. The return on equity (ROE) is 3.45%, and the return on assets (ROA) is 3.13%. These figures suggest moderate profitability relative to its equity and asset base.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no detailed geographic breakdown provided, but the company is headquartered in South Korea and operates primarily within the region. This concentration may expose the company to regional economic and regulatory risks.

Pharmicell's revenue for the latest period was KRW 17,810,623,010. Analysts have provided a mean price target of KRW 26,000, with a median and high target also at KRW 26,000. The mean recommendation is 2.00, indicating a "Buy" rating. The company's growth trajectory is supported by its strong cash position and positive free cash flow of KRW 3,345,827,990.

The risk assessment indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags detected. The company's capital expenditure was negative at KRW -3,676,886,660, suggesting a reduction in capital spending. The operating cash flow was negative at KRW -2,485,804,480, which may be due to high capital expenditures or other operational factors.

Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company continues to focus on its core business of regenerative medicine and cell therapy, with no major new product launches or strategic acquisitions reported in the latest period.

Pharmicell Co Ltd (005690.KS) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals & Medical Research. This medium-severity update establishes the company’s operational identity, moving from an unclassified state to a defined position within the healthcare industry framework. Concurrently, the firm’s risk profile has been initialized with low ratings for both dilution and liquidity risks. These assessments, classified as low severity, indicate that the company currently faces minimal threat from share dilution and maintains adequate liquidity conditions according to the specified thresholds. The establishment of these fundamental metrics provides a baseline for future analysis, although the company currently lacks coverage from analysts, index memberships, or disclosed top holders. This absence of external market participants suggests limited public scrutiny or institutional engagement at this stage. These structural clarifications matter as they define the parameters for evaluating Pharmicell’s financial health and industry positioning. By confirming low risk in key areas and specifying its sector, the data supports a clearer understanding of the company’s stability within the pharmaceutical and medical research landscape.

Analysts project 132.6% upside to a consensus target price of 26,000 KRW, signaling strong market confidence.

Debt-to-equity ratio of 0.01 is well below the 0.18 cohort median, suggesting a conservative capital structure.

Cash conversion ratio of -0.88 ranks in the bottom quartile, suggesting poor cash generation relative to earnings.

Revenue CAGR of -1.7% over four years indicates a long-term trend of shrinking top-line growth.

Revenue KRW 114.06B, +75,9% YoY; Operating income +611,4% YoY.

• ▍Revenue KRW 114.06B, +75,9% YoY
• ▍Operating income +611,4% YoY
• ▍Net income +536,4% YoY
• ▍Free cash flow +577,7% YoY
• ▍Net margin 35.3%

Revenue KRW 64.85B, +15,3% YoY; Operating income +70,5% YoY.

• ▍Revenue KRW 64.85B, +15,3% YoY
• ▍Operating income +70,5% YoY
• ▍Net income +77,0% YoY
• ▍Free cash flow +1 169,2% YoY
• ▍Net margin 9.8%

Revenue KRW 60.18B, +16,2% YoY; Operating income +9,0% YoY.

• ▍Revenue KRW 60.18B, +16,2% YoY
• ▍Operating income +9,0% YoY
• ▍Net income +15,2% YoY
• ▍Free cash flow −185,4% YoY
• ▍Net margin 18.1%